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Abstract Breast cancer is the most common malignancy
in women and a significant cause of morbidity and mor-
tality. Sub-types of breast cancer defined by the expression
of steroid hormones and Her2/Neu oncogene have distinct
prognosis and undergo different therapies. Besides differing
in their phenotype, sub-types of breast cancer display var-
ious molecular lesions that participate in their pathogenesis.
BRCA1 is one of the common hereditary cancer predispo-
sition genes and encodes for an ubiquitin ligase. Ubiquitin
ligases or E3 enzymes participate together with ubiquitin
activating enzyme and ubiquitin conjugating enzymes in the
attachment of ubiquitin (ubiquitination) in target proteins.
Ubiquitination is a post-translational modification regulat-
ing multiple cell functions. It also plays important roles in
carcinogenesis in general and in breast carcinogenesis in
particular. Ubiquitin conjugating enzymes are a central
component of the ubiquitination machinery and are often
perturbed in breast cancer. This paper will discuss ubiquitin
and ubiquitin-like proteins conjugating enzymes partici-
pating in breast cancer pathogenesis, their relationships
with other proteins of the ubiquitination machinery and
their role in phenotype of breast cancer sub-types.
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Introduction
Breast cancer is the most common malignancy in women
and about one in eight women will be attained by the
disease during her lifetime. Increasing understanding of its
molecular pathogenesis has led to the definition of several
sub-types with corresponding progress in treatments for
some of these sub-groups [1]. Genomically-defined sub-
types are not used in clinical practice due to practical
issues. Instead, an approximate equivalent of genomic sub-
groups used in clinical practice is based on immunohisto-
chemical (and/or in situ hybridization) evaluation of a few
proteins including estrogen receptor alpha (ERa), proges-
terone receptor (PR), Her2/Neu (a member of the epider-
mal growth factor receptor family) and the MIB-1 antigen
(also named Ki-67) as a measurement of proliferation [2].
These evaluations are important for prognostication and
therapeutic decisions as the sub-types defined in this
manner have significantly different prognosis and may
receive different treatments.
Ubiquitination (also referred to as ubiquitylation) is one of
several post-translational protein modifications which reg-
ulates virtually every function of the cell and involves the
covalent attachment of one or several molecules of the pro-
tein ubiquitinin to a target protein. It is carried out by a
stepwise process executed with the help of three enzymes, a
ubiquitin-activating enzyme (also called E1), a ubiquitin-
conjugating enzyme (or E2) and a ubiquitin ligase (or E3) [3,
4]. There also exist several ubiquitin-like proteins (UBLs)
that can similarly be attached to target proteins with the help
of an analogous to ubiquitin enzymatic cascade. These
include small ubiquitin-like modulator (SUMO), neural
precursor cells expressed and developmentally down-regu-
lated 8 (NEDD8), interferon-stimulated gene 15 (ISG15) and
HLA-F adjacent transcript 10 (FAT10) [5].
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Ubiquitination is a versatile post-translational modifi-
cation. Ubiquitin is a 76 amino-acids molecule and has
seven lysine residues at positions 6, 11 27, 29, 33, 48 and
63. Attachment through each of these lysine residues as
well as through the amino-terminal methionine residue has
been confirmed to possess signaling potential [6, 7]. The
number of ubiquitin molecules attached encodes also for
different outcomes [8]. A target protein may become
mono-ubiquitinated (a single ubiquitin molecule attached),
multi-ubiquitinated (one ubiquitin molecule attached in
several different lysine residues of the target protein) or
poly-ubiquitinated (a chain of ubiquitins attached through
the same lysine residue).
The importance of ubiquitination in breast cancer is
exemplified by the fact that protein BRCA1, one of the
proteins mutated in hereditary breast cancer syndromes, is
a ubiquitin ligase. Moreover several key proteins in breast
cancer and actual or potential targets of therapy such as
ERa, PR and transcription factor NF-jB are regulated by
ubiquitination and UBLs modifications. Ubiquitin conju-
gating enzymes that co-operate with BRCA1 as well as
with other E3 ligases to perform ubiquitination or UBLs
conjugation have also a role in breast cancer and will be
discussed in this paper.
E2 enzymes
Ubiquitin-conjugating enzymes are situated in the middle of
ubiquitin and UBLs enzymatic conjugation cascade
between the ubiquitin-activating enzymes and the ubiquitin
ligases. The number of E2s in the human genome is more
limited than E3 ligases. There are about 35 E2s scattered
across almost all human chromosomes, while there are more
than 600 E3s in human genome belonging to two main
types, the RING type and HECT type [9]. There are two E1
enzymes performing ubiquitination in humans UBA1 and
UBA6, the latter serving also the FATylation (conjugation
of FAT10) cascade. Other UBLs have dedicated E1 s, for
example the heterodimer APPBP1/UBA3 is the E1 for
NEDD8 and UBE1L is the E1 for ISG15. E2 enzymes
interact with E1 enzyme that carries the activated ubiquitin
and accept ubiquitin forming a thiolester bond using its
active site cysteine. A conformational change in E1 occur-
ring only after ubiquitin loading allows this interaction.
After the transfer to E2, E1 retakes its prior conformation
which promotes dissociation of the ubiquitin molecule-
loaded E2 [10]. This is followed by an interaction of the
ubiquitin-loaded E2 with an ubiquitin ligase and transfer of
ubiquitin directly on a substrate concomitantly attached to
E3, in the case of RING type E3s, or to a cysteine residue of
the E3, in the case of HECT type E3s, which then transfers it
to the substrate. A similar enzymatic cascade takes place for
the attachment of ubiquitin-like molecules such as SUMO,
NEDD8 and ISG15 but it uses specific enzymes some of
which may also function in ubiquitination but others such as
the SUMO E2 and E3s function uniquely in this ubiquitin-
like molecule attachment. E2s are structurally characterized
by a conserved domain of about 150–200 amino-acids called
ubiquitin-conjugating (UBC) fold which serves as a plat-
form for E1, E3 and ubiquitin binding (Fig. 1a). The cata-
lytic cysteine is embedded in this domain. About 10 residues
amino-terminal to the catalytic cysteine there usually exist
an histidine, proline, asparagine (HPN) motif which plays
roles in the active site formation of the isopeptide bond
between ubiquitin and the e amine group of a lysine in the
substrate protein [11]. The general structure of the UBC fold
comprises four a helices, a four-stranded b-sheet, and a
small 310 helix (a helical structure with hydrogen bonds
between the amino-acids separated by two other amino-
acids, while in a helices these bonds link amino-acids sep-
arated by three amino-acids in between). Two loops
between the b-sheet and the active site and between the
second and third a helix are also important in the formation
of the shallow groove that surrounds the active cysteine. The
active cysteine accepting ubiquitin or a UBL is found after
the fourth b-sheet strand and immediately amino-terminal to
the small 310 helix in a shallow groove constructed, in
addition to these two structures, by residues from the third
and fourth a helices [12] (Fig. 1b). The first a helix and two
loops between the third and fourth b strand and between the
small 310 helix and the second a helix constitute the inter-
acting surface with E3s. Except from the UBC fold several
E2s have additional domains amino-terminal or carboxy-
terminal to UBC or both. A classification based on the
presence of these additional domains has been introduced in
which E2s without additional domains besides UBC fold are
considered class I, E2s with amino-terminal to UBC fold
extensions are class II, E2s with carboxy-terminal exten-
sions are considered in class III and those with both amino-
and carboxy-terminal extensions are considered as belong-
ing in class IV [13] (Fig. 1c).
The recognition of the target protein to be modified is
mainly a task of the ubiquitin ligase involved. In contrast,
in many occasions, the E2 enzyme plays a significant role
in the type of ubiquitin link or chain to be attached, at least
when co-operating with RING type E3s. This is very
important because the type of attachment defines the ulti-
mate outcome. A lysine 48 linked chain of at least four
ubiquitin molecules and lysine 11 chains result for example
in recognition of the target protein by the proteasome for
degradation, while lysine 63-linked ubiquitination leads to
lysosome-mediated degradation or non-degradative out-
comes [14]. Another task in which E2 enzymes play an
important role in collaboration with the specific E1 enzyme
is the recognition of the E1 and the fidelity of transferring
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only their cognate UBL molecule and of concomitantly
excluding all others [15]. In addition, E2s are significant in
the processivity of the assembled ubiquitin chains forma-
tion. This refers to the number of ubiquitins that an E2 may
add in a single interaction with a given E3 to a given target
protein and depends on the affinity of the substrate for the
E3 and on the rate of E2 catalysis [16].
An E2 enzyme may co-operate with several E3s and
participate to the ubiquitination of several different sub-
strate proteins and conversely an E3 ligase may use dif-
ferent E2s for performing attachment of diverse ubiquitin
modifications. For example E2 UBE2L3 (UbcH7) may
co-operate with both RING type casitas B cell lymphoma
(E3 c-Cbl) [17] and HECT type E3 E6-associated protein
(E6AP) [18] and conversely E3 ligase APC/C co-operates
with two E2s UBE2C and UBE2S to perform substrate
mono-ubiquitination and lysine11 poly-ubiquitination
respectively.
Regarding their nomenclature, E2s were initially given
various names that did not denote their function. In an
effort to systematically categorize E2s in a homogeneous
manner, a name consisting of the designation ubiquitin
enzyme E2 (UBE2) followed by a serial capital letter
according to their consecutive discovery has been pro-
posed and will be used in the subsequent discussion [13].
Alternative names commonly used in the literature will
be given in the first encounter of each enzyme in the
discussion.
Specific E2 enzymes with a role in breast cancer
Several E2 enzymes taking part in ubiquitination or UBLs
conjugation have been studied and found to play a role or be
altered in breast cancer (Table 1). Depending on the sub-
strate protein conjugated, important processes in carcino-
genesis such as transcription, DNA repair, chromosome
segregation during mitosis and apoptosis may be affected.
UBE2I (Ubc9), the SUMO conjugating enzyme
UBE2I is the only known E2 enzyme for the SUMOylation
cascade. This cascade uses the heterodimeric AOS1/UBA2
as the E1 enzyme and several E3s. UBE2I being the sole
E2 in SUMOylation, perturbations of its expression or
function may theoretically influence all the processes in
which SUMOylation plays a regulatory role. These include
DNA damage response, DNA transcription and an
increasing number of signaling cascades. Specific exam-
ples pertaining to breast cancer include ERa signaling and
transcription regulation, BRCA1-dependent DNA repair
and transcription and NF-jB signaling. Other proteins that
are targets of SUMOylation may play a role in breast
cancer. SUMO tags function basically through two mech-
anisms [19]: In some cases they promote protein–protein
interactions through binding of a protein containing a
SUMO interactive motif (SIM) to a SUMO-tagged protein
(Fig. 2, upper panel). In other cases SUMO prevents
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Fig. 1 a. Linear representation of the conserved UBC fold of E2
enzymes. The first a helix is followed by the four-stranded b-sheet
which is connected with the 310 helix by a loop containing the active
cysteine and the HPN motif. Three additional a helices are more
carboxy-terminally in the UBC fold. H a helices, S strands of the
b-sheet, L loops between a helices and strands of the b-sheet, C active
cysteine, HPN histidine–proline–asparagine motif. b 3D representation
of the UBE2C homolog from clam, E2-C. a helices are represented in
red and b-sheet in blue. From Jiang and Basavappa [131]. c Classifi-
cation of E2s and examples of each class playing a role in breast cancer
and discussed in the paper. Class I E2s have only the UBC fold, class II
have amino-terminal additional domains, class III have carboxy-
terminal extensions and class IV both amino-terminal and carboxy-
terminal extensions
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protein–protein interactions, for example by binding to the
same lysine residue of a protein that also could bind
ubiquitin [20] (Fig. 2, lower panel). In this manner a
SUMO-tagged protein is prevented from interacting with a
protein possessing an ubiquitin-binding motif. SUMOyla-
tion plays a role in the transcription function of several
transcription factors including ERa [21]. ERa signaling is
implicated in the physiologic development of mammary
gland but also in breast cancer [22]. The majority of breast
cancers express ERa and activation of this receptor by
estrogens promotes cell proliferation and survival. Endo-
crine therapies used clinically in ERa expressing breast
cancers work by blocking ERa signaling through inter-
ruption of ligands binding or through inhibition of estrogen
production or down-regulation of the receptor itself. After
estradiol ligation ERa binds to DNA either directly through
ER specific elements or indirectly through tethering to
other transcription factors. Nuclear receptor binding trig-
gers recruitment of co-factors leading to chromatin
remodeling and further recruitment of basal transcription
machinery for transcription to start. SUMOylation ranks
among the modifications that take part in ERa transcription
regulation despite the fact that ERa protein possesses no
consensus SUMOylation sequence [23]. It takes place only
after ligand binding to the receptor through conserved
residues in the hinge region of ERa molecule and with the
co-operation of UBE2I with SUMO E3 ligases protein
inhibitor of activated STAT 1 (PIAS1) and PIAS3 [23].
SUMOylation positively modulates transcriptional activity
of ERa. UBE2I may also have a role in ERa transcription
regulation independently from its SUMO-conjugating
activity based on the fact that mutant UBE2I disabled for
conjugation is still able to modulate ERa transcription. In
addition to ERa itself the transcriptional co-activator of
ERa steroid receptor co-activator 3 (SRC3, also known as
AIB1, amplified in breast cancer 1 or NCOA3, nuclear
receptor co-activator 3) is a target of SUMOylation [24].
SRC3 SUMOylation is facilitated by PIAS1 and inhibits
the interaction of SRC3 with ERa, suppressing ERa tran-
scriptional activity and prolonging the stability of SRC3 in
breast cancer cells [24].
BRCA1 is a protein playing roles in DNA repair and is
mutated in hereditary cases of breast cancer. In addition, it is
dysfunctional in sporadic breast cancers that exhibit features
of hereditary breast cancer biology such as negativity for the
expression of ERa and PR receptors and absence of ampli-
fication of Her2/Neu receptor (the so-called triple negative
phenotype). These similarities have led to coining the term
‘BRCAness’ to include breast cancers with defective
BRCA1 activity either due to germline mutations or somatic
dysfunction [25]. BRCA1 is a RING finger E3 ubiquitin
ligase which participates in the repair of double strand DNA
breaks in the homologous recombination pathway. It is
recruited at sites of double strand DNA damage together with
its partner BRCA1 associated RING domain (BARD1), a
protein with a RING domain but without innate ligase
activity. This recruitment depends on phosphorylation of
histone H2AX by damage sensing kinases ATM and ATR
and previous recruitment of E3 ligases RNF8 and RNF168
which ubiquitinate histones H2A and H2AX around the
damaged site. Ubiquitinated histones help directly or indi-
rectly in the accrual of protein receptor associated protein 80
(RAP80) which then recruits BRCA1 [26]. Both RAP80 and
BRCA1 are targets of SUMOylation and this modification is
required for BRCA1 localization to sites of DNA damage
and augments its ubiquitin ligase activity [27, 28]. RAP80
SUMOylation takes place in its amino-terminal part with the
help of UBE2I [29] and an unknown ligase.
Besides double strand DNA repair by homologous
recombination, BRCA1 participates in cell cycle checkpoint
signaling and transcription regulation including transcrip-
tion of ERa gene. BRCA1 cell cycle checkpoint control
complexes have many participants in common with DNA
damage repair [30] and thus SUMOylation is expected to
Table 1 Examples of E2 enzymes playing a role in breast cancer, their target UBLs, co-operating E3s, target proteins modified and processes
that are regulated
E2 UBL E3 Targets Processes
UBE2I SUMO PIAS1 BRCA1, ERa, NF-jB Transcription, DNA repair
UBE2C Ubiquitin APC/C Securin, cyclin B Cell cycle
UBE2S Ubiquitin APC/C Securin, cyclin B Cell cycle
UBE2D Ubiquitin BRCA1, ERa, p53 Transcription, apoptosis
bTrCP IjBa NF-jB regulation
UBE2B Ubiquitin Mdm2 p53 Apoptosis, cell cycle arrest
UBE2L3 Ubiquitin ? PTEN Signal transduction
UBE2L6 ISG15 HERC5, EFP Signal transduction, invasion
UBE2M NEDD8 Rbx1, Rbx2 Cullin E3 ligases NF-jB regulation
UBLs ubiquitin-like proteins, PIAS1 protein inhibitor of activated STAT 1, APC/C anaphase promoting complex/cyclosome, HERC5 HECT and
RLD domain-containing E3 ligase 5, EFP estrogen-responsive RING finger protein, Rbx RING box proteins
2022 Mol Biol Rep (2013) 40:2019–2034
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play roles in this process. BRCA1 SUMOylation in an
amino-terminal consensus sequence is required for repres-
sion of ERa activity by BRCA1-dependent ubiquitination
[31, 32]. UBE2I participates in BRCA1 SUMOylation as
well as its nuclear localization and retention [33]. It is worth
mentioning here that SUMOylation is a nuclear localization
signal for several proteins [20, 34, 35]. In breast cancer cells,
for example, SUMOylation and UBE2I over-expression
promote nuclear accumulation of receptor kinase IGF-1R
after ligand binding where it acts as a transcription factor [36,
37]. In an additional twist of the tale SUMO suppresses
BRCA1-regulated transcription independently of SUMOy-
lation [38]. This effect depends on the recruitment of
deacetylases on the promoter of BRCA1-regulated genes and
takes place even in cells expressing a dominant negative
UBE2I impairing SUMOylation [38]. How this effect is
mechanistically mediated remains unknown although one
could speculate that free SUMO competes with bound
SUMO for protein interactions.
NF-jB represents a family of transcription factors with a
role in inflammation and carcinogenesis. The role of
ubiquitination in NF-jB regulation is well-established and
indeed NF-jB inhibition was one of the first mechanisms
proposed for the explanation of the anti-tumor activity of
proteasome inhibitors, although it is now clear that addi-
tional targets of this inhibition is clinically relevant [39].
Ubiquitin modifications leading to proteasome degradation
and non-degradational outcomes involve many NF-jB
pathway components. SUMOylation is an additional player
in NF-jB regulation. The inhibitor of NF-jB IjBa is an
example of regulation by SUMOylation. SUMO binding
takes place through the same lysine residue of IjBa that
also binds ubiquitin. SUMOylation of this lysine in
response to adenosine signaling prevents ubiquitin binding
and stabilizes IjBa inhibiting NF-jB [40]. Given that
IjBa ubiquitination is regulated by both previous phos-
phorylation and by NEDDylation (attachment of the
ubiquitin-like protein NEDD8) which activates the E3
ligase bTRCP, degradation of this key inhibitor of NF-jB
is co-ordinated by at least four post-translational modifi-
cations securing a tight control of the pathway and allow-
ing activation only if several prerequisite conditions are
fulfilled (Fig. 3). SUMOylation also regulates NF-jB a
step above IjBa at the level of the IKK complex by
modulation of IKKc (also named NEMO, NF-jB essential
modulator) [41]. This modification appears to take place
specifically following DNA damage and not after other
NF-jB-activating signals and thus defines distinct modes
for activation of the same transcription factor possibly
helping to fine-tune this activation. Two other E2 enzymes,
UBE2D2 and UBE2D3, participating in the regulation of
NF-jB signaling by ubiquitination will be discussed in a
later section.
NF-jB activation has been linked with endocrine
treatment resistance of ERa positive breast cancer [42] and
with sensitivity or resistance to neo-adjuvant chemotherapy
SUMO-ylated
protein
SUMO SIM-containing protein
SUMO-ylated
protein
SUMO
Ubiquitin
UIM-containing 
protein
Fig. 2 Mechanisms of
SUMOylation function. In the
upper panel SUMOylation
promotes the interaction of the
SUMO-decorated protein with
another protein that bears a
SUMO interacting motif (SIM).
In the lower panel SUMO
competes with ubiquitin for the
same lysine of a substrate
protein preventing
ubiquitination. Ubiquitin
interacting motif (UIM)—
containing protein is prevented
from interacting with the
SUMOylated protein
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[43–45]. These contradictory results regarding the role of
NF-jB in chemotherapy resistance probably relate to dif-
ferent sub-types of breast cancer studied, different sub-
units of NF-jB examined that may play differing roles [46]
and the fact that the canonical and non-canonical NF-jB
pathways have distinct roles in the epithelial breast cell
hierarchy [47]. An additional experimental factor to con-
sider when evaluating those results relates to immunohis-
tochemistry which measures the expression or the nuclear
presence of the transcription factor but is not able to inform
functionality, a major limitation when studying transcrip-
tion factors solely with this method.
UBE2I has been found to be up-regulated in breast cancer
initiating cells due to down-regulation of microRNA miR-30
in these cells [48]. miR-30 reduction promotes the ability of
breast cancer initiating cells to self-renew and resist apop-
tosis and anoikis. Breast cancer xenografts expressing miR-
30 through a lentiviral vector system displayed reduced
growth in mice compared with control xenografts. Xeno-
grafts transduced with UBE2I targeting shRNA displayed
reduced growth but in a lesser degree suggesting that part of
the miR-30 effect is due to UBE2I but other targets of the
microRNA play a role. A proposed such target is integrin b3
which is a structural and signaling component of focal
adhesions with a role in cell motility [48]. UBE2I may also
have a role in breast cancer that is dependent on transcription
regulation of another miR, miR-224 but independent of its
SUMO conjugating activity [49]. This probably relates to its
function as transcription co-factor [50]. Acting indepen-
dently of protein SUMOylation, even a dominant negative
mutant UBE2I without SUMO-conjugating activity is able to
down-regulate expression of miR-224 which, in turn,
up-regulated CDC42 and CXCR4, two invasion-promoting
proteins [49]. Putative transcription factors co-operating
with UBE2I for miR-224 suppression have not been
reported.
UBE2I shows an increased expression in invasive ductal
carcinoma compared with normal breast and is associated
with larger and less differentiated tumors, nodal metasta-
ses, resistance to neo-adjuvant FEC chemotherapy and
decreased disease free survival [51]. A higher percentage
of triple negative and triple positive (ER/PR positive and
Her2 positive) patients had high UBE2I expression as
opposed to patients with ER/PR positive, Her2 negative
and ER/PR negative, Her2 positive tumors in whom the
percentage of high UBE2I expression was lower [51].
These data pinpoint to a role of high expression of UBE2I
in associating the expression of ERa and PR with Her2/
Neu while lower expression leads more often to dissocia-
tion of these expressions. A hypothesis on how these
molecular associations might take place is given in a sub-
sequent section.
UBE2C (UbcH10) and UBE2S (E2-EPF)
Two other E2 enzymes with a role in breast cancer are
UBE2C (also called UbcH10) and UBE2S (also called
E2-EPF) which are both working with E3 ligase anaphase
promoting complex/cyclosome (APC/C) in the regulation of
cell cycle. UBE2C co-operates with APC/C for the initial
ubiquitin attachment to substrates while UBE2S performs
with APC/C subsequent ubiquitin attachments producing
lysine 11 chains [52]. These enzymes are the only known
enzymes constructing ubiquitin chains through lysine 11. In
the end of the metaphase stage of mitosis chromosomes are
aligned at the equator of the cell and develop connections
through the centromere with both poles of the mitotic spindle
[6]. The completion of the attachment of all chromosomes to
both poles gives the signal for each sister chromatid to detach
from its pair and be pulled towards a spindle pole. Till this
signal is given sister chromatids are kept attached at the
centromere with the action of proteins cohesins. When all
chromosomes are attached, APC/C ubiquitinates the protein
securin, an inhibitor of the enzyme separase, and promotes
its degradation by the proteasome [53]. After securin
destruction, separase is activated and cleaves cohesins
allowing sister chromatids to be pulled to the two poles at
anaphase. In parallel APC/C promotes the destruction of
Cyclin B allowing dephosphorylation and inactivation of
CDK1, another prerequisite for progression from anaphase
to telophase and completion of mitosis [54]. In the end of
mitosis APC/C auto-regulates its action by ubiquitinating its
own activating factors and E2 enzymes [55].
Lysine 11 chains constructed by APC/C and E2s
UBE2C and UBE2S have a close configuration with
additional non-covalent attachments between the neigh-
bouring ubiquitin molecules similarly to lysine 48 chains
Fig. 3 Regulation of NF-jB signalling by inhibitor IjB post-
translational modifications. Only if all prerequisite conditions are
fulfilled will IjB be destroyed in the proteasome in order for NF-jB
to be activated
2024 Mol Biol Rep (2013) 40:2019–2034
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and are also recognized by the proteasome leading to
substrate degradation. Nevertheless they differ from lysine
48 in the kinetics of the degradation [56]. Thus the rec-
ognition of different ubiquitin chains by the proteasome
may serve the purpose of conferring different priorities in
proteasome destruction giving for example priority in
specific proteins in order for the cell cycle to proceed. The
timing of the destruction of different proteins is of para-
mount importance during the physiologic cell cycle pro-
gression and perturbations of the machinery that serves this
destruction may lead to carcinogenesis. Given the impor-
tance of cell cycle and mitosis regulation which includes an
error free and even distribution of chromosomes to
daughter cells, eukaryotic cells have dedicated a specific
ubiquitin linkage through lysine 11 and specific machinery
to this process possibly in order to avoid interferences with
other types of ubiquitin chains [57].
UBE2C is over-expressed in diverse tumor cell lines and
primary tumor tissues compared with normal tissues [58].
UBE2C over-expressing transgenic mice display whole
chromosome instability and are prone to spontaneous tumor
formation [59]. Breast cancer is among the carcinomas that
over-express UBE2C gene and protein [60] and there is a
correlation of this over-expression with higher grade of
carcinomas [61], proliferation index as measured by the
Ki-67 antigen staining and Her2/Neu positivity [62]. High
expression of UBE2C mRNA by RT-PCR was found to be
associated with poor disease free and overall survival in
patients with breast cancer treated with adjuvant chemo-
therapy [63] and protein evaluation by IHC was a prognostic
marker for metastasis free and overall survival in another
series of node positive breast cancer patients [64]. In this last
study of 92 patients, a positive UBE2C staining (defined as
more than 11 % positive cells) added prognostic information
to the well-validated Nottingham Prognostic Index [64]. The
E2 enzyme UBE2S that co-operates with APC/C ligase for
the elongation of lysine 11 chains is also over-expressed in
the protein level in many breast tumors and often in corre-
lation with other cell cycle regulators [65]. An implication of
UBE2S in topoisomerase II inhibitors etoposide and doxo-
rubicin sensitivity has been suggested based on the fact that
knock-down of the conjugating enzyme in vitro sensitized
cells to the cytotoxicity of these inhibitors [65].
UBE2D2 and UBE2D3
UBE2D3 (UbcH5c) is one of the E2 partners of BRCA1/
BARD1 ubiquitin ligase heterodimer co-operating with this
ligase to build lysine 6 ubiquitin chains [66] in DNA damage
repair when, as discussed, BRCA1 is recruited to double
strand DNA damaged sites to participate to repair by
homologous recombination [67]. UBE2D3 is directly regu-
lated by the transcription regulator SLUG (also termed
SNAIL2) which recruits co-repressor CtBP1 and histone
deacetylase HDAC1 to the UBE2D3 promoter and represses
its expression [68]. UBE2D3 participates in the ubiquitina-
tion and degradation of cyclin D1 which is stabilized after
UBE2D3 suppression and promotes proliferation of breast
cancer cells in vitro [68]. In addition cyclin D acts as an ERa
transcription co-activator, competing with BRCA1 for
receptor binding [69]. In this manner SLUG which is a
core transcription regulator of epithelial to mesenchymal
transition program, links proliferation with invasion and
metastasis (Fig. 4). Nevertheless a study of 25 mostly non-
metastatic breast cancers found increased expression of
UBE2D in cancer specimens compared with adjacent nor-
mal tissue [70]. This increase was specific for breast cancer
because colorectal cancer samples did not show an increased
UBE2D expression. The rabbit polyclonal antibody used in
this study recognizes all three isoforms of UBE2D and thus it
is not possible to ascertain if this over-expression concerns
one or more of the three isoforms UBE2D1-3 of the conju-
gating enzyme. Thus, it remains plausible that increased
expression observed in breast cancer concerns also UBE2D2
isoform and confers a benefit for cancer cells by inhibiting
p53 and activating NF-jB through IjBa degradation (see
next).
UBE2D2 (UbcH5b) and UBE2D3 are E2 enzymes that
co-operate with ligase Mdm2 in the ubiquitination of p53
[71]. Their down-regulation in breast cancer cells in vitro
leads to accumulation of p53, but it is not sufficient to
induce p53 transcriptional activity [71]. This is possibly due
to the fact that Mdm2 is able to partially suppress p53
activity independently from its ligase activity. UBE2D2
and UBE2D3 participate also in NF-jB regulation by
co-operating with ligase b-TrCP in the degradation of
NF-jB inhibitor IjBa [72]. This is one of the most
important points of NF-jB regulation and is also regulated
by additional post-translational modifications as previously
described (Fig. 3). These effects of UBE2D in p53 and
NF-jB regulation may contribute to cancer promotion in
early breast cancer with over-expression of UBE2D [70]. It is
tempting to speculate that, in more advanced cases with
SLUG over-expression and features of EMT, UBE2D
becomes down-regulated, an event that would also promote
ERa transcription suppression and genomic instability
through BRCA1 dysfunction.
Ube2b
UBE2B (hHR6B or Rad6B) is an E2 enzyme that together
with the highly homologous UBE2A (hHR6A or Rad6A)
contribute to DNA repair [73]. UBE2B is up-regulated
following adriamycin-induced DNA damage in breast
cancer cells and is localized to sites of damage [74].
UBE2B plays also a role in stabilization of b-catenin [75].
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This effect is mediated by building of Lysine 63 ubiquitin
chains in contrast to Lysine 48 chains which are built with
the aid of ligase bTrCP and lead to proteasome degradation
[75]. The Wnt/b-catenin signalling pathway is important in
development but also in carcinogenesis. Its activation
promotes EMT in epithelial cancers and metastasis [76]. In
addition of being a positive regulator of b-catenin, UBE2B
is a target gene of the Wnt/b-catenin pathway completing a
positive feed-forward loop [77, 78].
UBE2B forms a complex with ligase Mdm2 that leads to
p53 degradation [79]. This complex is dissociated in stress
conditions when the conjugating enzyme is freed and
accumulates on chromatin, participating in histone meth-
ylation and induction of p53 transcriptional activity [79]. It
is evident that Mdm2 co-operates with different E2
enzymes for the regulation of p53 stability [71, 79] but the
functional status of p53 differs after E2-E3 dissociation
depending on the E2 participating in the initial complex.
UBE2B supports p53 transcriptional activity whereas if
UBE2D2 or UBE2D3 were the initial partners, p53 is
stabilized without transcriptional activation. The choice of
different E2 that participate in p53 regulation may depend
on their expression in different cell types or other post-
translational modifications. For example phosphorylation
of UBE2B by CDK kinases has been reported to affect its
functional capability in breast cancer cells [80]. As a result
of the base-line availability and functionality of the E2s, a
cell that possesses a functional p53 may respond differently
to stress by activating p53-dependent transcription or sta-
bilization of p53 without initializing transcription. In an
integrative scenario p53 associated with UBE2D3 could
represent an inactive and non-degradable pool of p53
protected from UBE2B-Mdm2 degradation and in constant
equilibrium with it. In stress conditions the equilibrium is
flipped towards the UBE2B-Mdm2 complex because there
is a signal for dissociation that creates free UBE2B mole-
cules. These molecules can either promote p53 transcrip-
tion activity or participate with newly synthesised Mdm2 to
new p53-Mdm2-UBE2B complexes in a negative feed-
back loop (Fig. 5). Additional regulators such as the Mdm2
partner Mdm4 (also known as Mdmx) fine-tune p53 sta-
bility and function [81].
In a study of 20 patients with breast cancer of various
molecular subtypes receiving neo-adjuvant doxorubicin-
based chemotherapy, patients with higher UBE2B nuclear
staining had a higher clinical response rate than patients with
lower expression of the E2 enzyme [82]. Nevertheless, there
was no statistically significant difference in pathologic
response between higher and lower nuclear expressors pos-
sibly due to the low number of patients in the study [82]. As a
result the confirmation of a possible predictive role of
nuclear UBE2B in neo-adjuvant chemotherapy of breast
cancer awaits further studies. Mechanistically a nuclear
localization of UBE2B would be expected to have a role in
therapeutic response to chemotherapeutic drugs. This
response could follow a dissociation of p53 from the
UBE2B-Mdm2 complex after drug-induced stress. Of
interest there was no association of Rad18, a known factor
localizing UBE2B to damaged sites, with nuclear localiza-
tion of UBE2B and thus other factors are probably mediating
this recruitment following chemotherapy [82].
Other E2s with a role in breast cancer
Additional E2s have been reported to have a role in breast
cancer cell proliferation. E2 UBE2L3 (UbcH7) regulates the
UBE2D3
HDAC1
CtBP1
Slug
Cyclin D
ERα
BRCA1
MDM2 βTrCP
p53 I  B
Fig. 4 Schematic representation of the roles of ubiquitin conjugating
enzyme UBE2D3 in breast cancer. UBE2D3 co-operates with RING
type ligases BRCA1, Mdm2 and bTrCP to down-regulate ERa, p53
and IjB respectively. It also interferes with ERa transcription
function by antagonizing cyclin D. Epithelial to mesenchymal
transition regulator slug is a repressor of UBE2D3 in co-operation
with factor CtBP1 and deacetylase HDAC1
p53
p53
p53
UBE2B
UBE2D3Mdm2
UBE2B
Stress
Mdm2
proteasome
Stabilization
In inactive state
Fig. 5 Model of regulation of tumor suppressor p53 by E2 enzymes.
Association with conjugating enzyme UBE2D3 prevents binding to
Mdm2-UBE2B and stabilizes p53 in an inactive form. Binding to
Mdm2-UBE2B promotes ubiquitination and proteasome degradation
of p53 but also allows in stressful conditions the activation of the
transcription factor after dissociation of Mdm2 and UBE2B. In these
conditions UBE2B associates with chromatin and acts as a p53
co-activator for the transcription of Mdm2 and other target genes
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abundance of phosphatase PTEN in breast cancer cells.
Immuno-precipitation experiments showed that UBE2L3 as
well as the SUMO E2 UBE2I associate with PTEN [83].
Signalling by the bone morphogenetic protein (BMP)
pathway decreases these associations and may stabilize
PTEN (Fig. 6). UBE2L3 also acts as a co-activator of
nuclear receptors including ERa and PR [84]. Co-activation
requires the enzymatic activity of UBE2L3 and the presence
of co-activator steroid receptor co-activator 1 (SRC1) on the
promoter site occupied by the hormone-bound steroid
receptor. Knock-down of UBE2L3 in breast cancer cells
reduced the transcriptional activity from the PR promoter. In
addition, exogenous administration of UBE2L3 was able to
reduce squelching that is observed between ERa and PR-
dependent transcription due to competition for limiting
amounts of co-factors, implying that the conjugating
enzyme is critical for both ERa and PR transcription [84].
UBE2L3 has been found to bind the BRCA1/BARD1 dimer
but is unable to co-operate with it in ubiquitination [85]. It
has been suggested that this interaction interferes with
ability of BRCA1/BARD1 dimers to trigger an intra-S phase
checkpoint of the cell cycle [86]. It would also be interesting
to examine if this interaction interferes with the BRCA1
repressing activity on ERa transcription.
The conjugating enzyme UBE2L6 (UbcH8) is the E2 for
the ubiquitin-like protein ISG15 also called, ubiquitin
cross-reacting protein (UCRP). ISG15 was initially iden-
tified as one of the proteins up-regulated following treat-
ment of cells with interferon-a and -b and has two domains
homologous to ubiquitin. As a result the whole molecule
has a structure similar to an ubiquitin linear dimer
[87]. ISGylation, the conjugation of ISG15 to target
proteins, antagonizes in many occasions ubiquitination
of these proteins and results in their stabilization by
inhibiting proteasome degradation in a manner analogous
to SUMOylation [88]. ISG15 expression is elevated in
breast cancer cells [89] and both ISG15 and UBE2L6
contribute to cell motility and invasion by interfering with
the ubiquitin–proteasome system and by modifying the
function of proteins with roles in signal transduction such
as the JAK/STAT and MAPK pathways [90–92]. In con-
trast, stable knock-down of UBE2L6 by a small hairpin
RNA in breast cancer cell lines increased focal adhesions
and decreased cell motility in a wound healing assay
in vitro [90]. Elevated ISG15 in cancer cells may confer
sensitivity to topoisomerase I inhibitors camptothecins
(used clinically as anti-neoplastic drugs) by blocking the
ubiquitin-dependent repair of camptothecin-induced DNA/
topoisomerase I complexes [93]. Interestingly, knock-down
of the tumor suppressor BRCA2 associated with hereditary
breast cancer results in a decrease of both UBE2L6 and
ISG15 in breast cancer cells [94].These results suggest an
explanation for the association of BRCA2-mutated breast
cancers with resistance to certain drugs.
The role of the voluminous E2 enzyme Apollon (also
named BIRC6 or BRUCE but has no UBE2 designation)
has been investigated in breast cancer cells [95]. Apollon is
a class IV E2 that has an amino-terminal BIR [Baculoviral
inhibitor of apoptosis (IAP) repeat] domain and a carboxy-
terminal conjugating enzyme domain. It antagonizes
apoptosis by suppressing p53 activity [96] and by partici-
pating in the degradation of protein second mitochondria-
derived activator of caspases/direct IAP binding protein
with low isoelectric point (SMAC/DIABLO) [97]. It also
plays a role in abscission, the very late event of mitosis
when the final bridge between the two daughter cells is cut
[98]. In breast cancer cells knock-down of Apollon leads to
decreased proliferation and enhanced apoptosis associated
with p53 stabilization and caspase 3 activation [95]. Nev-
ertheless, it remains to be investigated if Apollon has a role
in human breast cancers in vivo.
UBE2T (HSPC150) is an E2 enzyme that regulates
proteasome degradation of BRCA1 [99]. It is up-regulated
in breast cancer cell lines and clinical samples. Its knock-
down by RNA interference caused BRCA1 up-regulation
and cell growth inhibition [99]. Thus UBE2T may be one
of the proteins whose up-regulation contributes to dys-
function of BRCA1-related processes in breast cancers that
have wild type BRCA1 (Fig. 6).
The NEDDylation pathway is intimately involved in
ubiquitination reactions mediated by RING E3 ligases of
the cullin sub-family because these ligases require NED-
Dylation for proper function [100]. The role of NEDDy-
lation in the regulation of NF-jB signalling has been
mentioned above. Additionally, NEDDylation regulates
ERa turn-over in breast cancer (Fig. 6). The NEDDylation
conjugating enzyme UBE2M (also called Ubc12) partici-
pates in this process and the presence of mutated UBE2M
in breast cancer cells stabilizes the receptor [101].
ERα
PRPR
UBE2L3UBE2T
BRCA1
UBE2M
PTEN
Fig. 6 A conjugating enzyme network regulating steroid receptors in
breast cancer. E2 UBE2T inhibits BRCA1, indirectly promoting ERa
transcription. NEDDylation E2 UBE2M participates in the turn-over
of ERa. UBE2L3 promotes ERa and PR transcription both directly
and in two indirect ways; by interfering with stability of BRCA1 and
of PTEN. This last event promotes kinase Akt signaling which is
involved in ERa activation independently from estrogens and is also
involved in hormonotherapy resistance. PR is a target of ERa. A
functional ERa leads to PR production which becomes available for
functioning as transcription factor
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Two homologous putative E2 ubiquitin conjugating
enzymes UBE2Q1 and UBE2Q2 have been shown to be
over-expressed in breast cancer tissues compared to adja-
cent normal breast in a subset of breast cancer cases
[102–104]. These enzymes have an amino-terminal RWD
(RING, WD repeat and DEAD-like) domain in addition to
their carboxy-terminal conjugating domain and may be
involved in the regulation of the cytoskeleton [103]. Thus
over-expression of these E2 enzymes in breast cancer
would lead to deregulation of processes involving the
cytoskeleton such as cytokinesis, adhesion and metastasis.
Ubiquitin conjugating enzymes and breast cancer
sub-types
The above discussion illustrates the role of ubiquitination
and other ubiquitin-like protein modifications in the patho-
genesis of breast cancer. These modifications regulate many
important molecular events in normal breast physiology and
breast carcinogenesis. UBC enzymes have, as a result, a
central role in these events. Important proteins in breast
cancer pathogenesis such as ERa, BRCA1 and NF-jB are
regulated by ubiquitin and UBLs attachment. Thus, the
machinery serving these attachments and E2 enzymes in
particular may have a defining role in breast cancer phe-
notypes, natural history and treatment response. BRCA1 is a
positive regulator of ERa expression and this fact may
explain the negativity of BRCA1 mutated breast cancers for
ERa [105]. Moreover it represses basal markers such as
cytokeratins 5 and 17 and P cadherin [106]. ERa negativity
makes these cancers concomitantly negative for the PR,
given that PR is an ERa transcriptional target [107]. In
addition, BRCA1 directly down-regulates PR activity by
inhibiting recruitment of additional PR molecules to pro-
moters and favouring recruitment of co-repressors instead of
co-activators [108]. PR serves as a transcriptional inducer of
receptor activator of NF-jB ligand (RANKL) and thus may
stimulate NF-jB signalling in a paracrine manner. This has
implications for understanding the regulation of ERa neg-
ative breast cancers by estrogens. In these cancers estrogens
may stimulate adjacent normal breast cells expressing the
receptor which then up-regulate PR and produce RANKL
which, in its turn, binds to RANK receptor on adjacent
neoplastic cells and stimulates them [109, 110]. The role of
BRCA1 in ERa expression regulation is independent of its
role in DNA damage repair. This also explains the fact that
cancers mutant for BRCA2, the other common culprit in
hereditary breast cancers, are not of a restricted phenotype.
Instead these cancers follow the distribution of sporadic
breast cancers, given that BRCA2 plays a role in DNA
damage repair but not in ERa expression. ERa down-reg-
ulation is associated with the aggressive phenotype of
epithelial to mesenchymal transition in breast cancer cells
[111]. As a result, despite being derived from a process
different from DNA damage repair in which BRCA1 par-
ticipates, i.e. ERa expression regulation, ERa negativity
leads also to aggressiveness and treatment resistance which
are both features of epithelial to mesenchymal transition.
Transcription factor NF-jB is a target of ERa transcrip-
tional repression and is thus up-regulated in ERa negative
breast cancer [112]. The small percentage of BRCA1 mutant
cancers with ERa positivity may be produced by a disso-
ciation of the two functions of BRCA1. In these cases
BRCA1 has a defective DNA repair function while it retains
the ability to positively regulate ERa. On the other hand, the
significant percentage of breast cancers with BRCA1 wild
type but ERa negativity may be produced by dysregulation
of BRCA1 function despite lack of mutations, for example
from defective post-translation modifications including
ubiquitination and SUMOylation. As mentioned in the
previous section, up-regulation of E2 UBE2T may lead to
BRCA1 down-regulation [99]. Alternatively ERa expres-
sion loss may be due to dysfunction of other ERa expression
regulators.
Recent data show that the phenotype of BRCA1 mutant
breast cancers depends on other concomitant mutations that
precede the loss of heterozygosity (LOH) in the BRCA1
locus [113]. If PTEN loss of function is present before this
LOH, cancers of a basal triple negative phenotype arise. In
the case that PTEN is functional, p53 mutations often pre-
cede BRCA1 LOH and luminal type cancers develop [113].
These data add another dimension in the regulation of breast
cancer phenotypes by E2s given that E2s UBE2L3 and
UBE2I participate in PTEN regulation [83]. PTEN loss of
function may also explain the third element of triple nega-
tivity, Her2/Neu lack of amplification or hyper-expression.
If PTEN is not functional the PI3K/Akt pathway down-
stream is up-regulated without the need of Her2/Neu ampli-
fication. In other words Her2/Neu amplification would not
offer additional benefit for the survival of cancer cells. It
would also explain the activation of NF-jB in triple negative
cancers, as this transcription factor is activated by kinase Akt
[114]. In addition the repressive role of ERa on NF-jB
transcription [112] is absent in triple negative cancers.
SUMO E2 UBE2I is over-expressed in many cases of breast
cancer and especially of the triple positive or triple negative
phenotype [51]. The association with triple negativity may
be related to down-regulation of BRCA1 function which
suppresses ERa expression and promotes at the same time
‘‘BRCAness’’ leading to PTEN loss of function which dis-
favours Her2/Neu amplification, as argued above. In contrast
the triple positivity may be associated with UBE2I over-
expression when, due to other concomitant regulations,
‘‘BRCAness’’ is absent, ERa remains expressed and pro-
motes PR expression leading to RANKL expression.
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Nevertheless, despite the expression of the two hormone
receptors, their function remains sub-optimal due to
SUMOylation deregulation and PR target gene RANKL is
not optimally produced. In addition, due to IjB SUMOyla-
tion, this inhibitor becomes more resistant to ubiquitination
and NF-jB becomes more refractory to activation. In this
scenario NF-jB becomes more dependent on additional
pathways for activation and thus amplification or hyper-
expression of Her2/Neu may confer additional advantage for
the cancer cell to obtain this activation. In breast cancers
which do not over-express UBE2I, ERa and PR function
normally and RANKL is produced to activate NF-jB with-
out the need for additional input. In addition, if hormone
receptors function well, cells may depend less on NF-jB for
survival [115]. This may explain the observed dissociation
of the expressions of hormone receptors from Her2/Neu
amplification [51].
Therapeutic perspectives
The UPS has been validated as a target of anti-cancer
treatment with the approval and use of the proteasome
inhibitor bortezomib in multiple myeloma. Other protea-
some inhibitors are in clinical development [116]. Never-
theless, in other malignancies bortezomib had not the same
success [117]. The exquisite sensitivity of myeloma to
proteasome inhibition may derive from the specialized
function of plasma cells which have the machinery for the
production of great amounts of immunoglobulins and
perturbations of this process may easily promote apoptosis
in these cells [118]. In contrast other malignant cells may
be less sensitive to such inhibition, being able to recom-
pense by various mechanisms. The proteasome possesses
three enzymatic activities. Bortezomib is a specific inhib-
itor of the chymotrypsin activity of the proteasome and,
although this is the most important enzymatic activity of
the three, the two other activities, trypsin and caspase-like,
may suffice to functionally substitute for this inhibition in
other than myeloma cell types. Indeed, in breast cancer cell
lines, acute exposure to bortezomib, even in concentrations
2 orders of magnitude higher than those that inhibit chy-
motrypsin activity by 95 % failed to stabilize ERa [119]. In
contrast chronic exposure to bortezomib in the same cells
down-regulated ERa by interfering with its transcription
[119]. Another reason for the failure of bortezomib in solid
tumors may relate to the lack of specificity of proteasome
inhibition. Dozens of proteins are proteasome substrates
and the net effect of up-regulations and down-regulations
following proteasome inhibition in each of them as part of
complex networks may lead to various outcomes in cancer
cells depending on the context. Two alternative strategies
could overcome this lack of selectivity. The first could be
interference with parts of the UPS besides the proteasome
per se that work with a more restricted set of partners.
A second strategy could target sub-sets of cancers with
specific characteristics or molecular lesions that would
make them sensitive to proteasome inhibition or sensitive
to modulation of other steps of the UPS. Inhibition of
specific ubiquitination enzymes or enzymes participating in
other UBLs modifications is an example of the first strat-
egy. NEDDylation is a post-translational modification that
often takes place in the Cullin component of the SCF type
RING ligases and helps the E2 enzyme binding to the
ligase complex in the ubiquitination cascade. MLN4924 is
a small molecule inhibitor of the NEDD8 activating
enzyme (NAE, the E1 for NEDD8) and is in early clinical
development [120]. Nevertheless the selectivity of this
intervention is only partial, given that RING ligases of the
SCF sub-family include several members and in addition
other proteins such as p53 and caspases are targets of
NEDDylation [121, 122]. As a result, it remains to be seen
if a sub-set of cancers with a particular sensitivity to this
drug can be defined. In breast cancer, interference with the
NEDDylation pathway could be a way to promote
expression of ERa in ERa negative cancers and promote
sensitivity to hormonal therapies.
Alternatively inhibition of specific E3 ligases or E2
ubiquitin conjugating enzymes could offer greater speci-
ficity. For example, inhibition of Mdm2 is a strategy in
development but it would be expected to be more effective
in cancers with wild type p53 [123]. Concerning E2
inhibitors, a specific conjugating enzyme inhibitor inhib-
iting the E2 UBE2R1 has been developed and shown to
inhibit ubiquitination of target protein CDK inhibitor p27
[124]. In another example of interference with specific E2
enzymes, it was shown that expression of a variant UBE2I
protein representing the amino-terminal part of the enzyme
interferes with the function of p53 and PTEN and syner-
gizes with chemotherapy to kill cells in vitro [125]. Clin-
ical development of E2 specific inhibitors has not started
yet.
The second strategy would involve defining malignan-
cies with specific molecular lesions that could be particu-
larly sensitive to ubiquitin–proteasome system function
inhibition as exemplified by multiple myeloma. This task
requires development of molecular markers that would be
easily and reproducibly performed in a clinical setting.
Protein p130Cas, an adaptor protein of cellular adhesions,
has been proposed as a marker of sensitivity to bortezomib
[126]. Cells that lack p130Cas are resistant to apoptosis
after bortezomib treatment and trigger autophagy while, in
contrast, cells expressing this protein are sensitive to pro-
teasome inhibition [126]. Nevertheless, p130Cas deficient
cells are concomitantly resistant to doxorubicin. Thus, it
remains possible that this resistance is generalized and
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related to adhesion destabilization and may not represent a
marker of resistance to particular treatments. Another
group of investigators proposed genome scale expression
profiling for defining proteasome inhibitor sensitive breast
cancer sub-sets and described a proteasome gene module
comprised of 50 genes including members of the protea-
some core and regulatory particles and ubiquitination
enzymes and regulators [127]. Breast cancer patients with
increased expression of this module had poorer metastasis-
free and overall survival than patients with low expression
of genes of the module. It was also shown that breast
cancer cell lines with high expression of the proteasome
module were more sensitive to bortezomib in vitro [127].
These data, if confirmed, beg for a ‘‘re-development’’ of
bortezomib specifically in the sub-set of breast cancer
patients with the proteasome gene signature. The same
drug development strategy based on marker-defined sub-
sets of sensitive cancers could be used for the development
of other drugs such as conjugating enzymes inhibitors. It
represents a more rational way of development than the
usual phase II model that includes all patients of a given
cancer type or location.
A final strategy to explore in ubiquitin–proteasome
system inhibitors development in breast cancer could be
the rational combination with other targeted therapies.
Such therapies already exist in breast cancer such as
trastuzumab, lapatinib and pertuzumab for the Her2/Neu
positive sub-type of the disease. Hormonal therapies also
represent a form of targeted treatment as they inhibit spe-
cific targets, ERa itself or the aromatase enzyme. Recently
PARP inhibitors have shown encouraging results in
BRCA1 and 2 mutant cancers [128] illustrating the concept
of synthetic lethality. Synthetic lethality refers to the
development of dependence of a cell to a pathway if a
lesion in a parallel pathway is present, so that if the first
pathway is pharmacologically inhibited the cell dies [129].
In BRCA mutated breast cancer homologous recombina-
tion is dysfunctional and cells depend on the base excision
repair pathway for DNA repair and are particularly sensi-
tive to inhibition of this pathway by PARP inhibitors.
Interestingly a state of ‘‘BRCAness’’ has been induced in
myeloma cells by bortezomib treatment and has sensitized
these cells to PARP inhibitor ABT-888 [130]. If the same
effect could be produced by ubiqutin-proteasome system
inhibition and PARP inhibition in BRCA wild type breast
cancer remains to be investigated. Inhibitors of the specific
E2 enzymes co-operating with BRCA1, if they were to be
discovered and developed, would also be rational candi-
dates for combinations with PARP inhibitors.
There are clearly ample opportunities for personalized
drug development in the field of UPS in breast cancer and
the future holds the hope that even metastatic breast cancer
will become a curable disease using molecular targeted
therapies alone or in combinations.
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